摘要
钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂是一种新型降糖药物,具有高选择性和特异性,可减少近曲小管对葡萄糖的重吸收,增加尿葡萄糖排出,从而达到降低血糖的目的。在治疗过程中发现,SGLT-2抑制剂在控制血糖的同时,对心脏及肾脏也产生保护作用。SGLT-2抑制剂可以通过降低患者体质量、改善能量代谢及降低血压等机制对心肾产生一定的积极作用。本综述简要阐述了SGLT-2抑制剂在临床诊疗过程中的重要地位及在心脏、肾脏方面所发挥的保护作用。
Sodium-glucose cotransporter-2(SGLT-2)inhibitors are a kind of novel hypoglycemic drug with high selectivity and specificity to reduce the reabsorption of glucose by proximal convoluted tubule and to increase urinary glucose excretion,thus achieving the purpose of reducing blood glucose.In the course of treatment,SGLT-2 inhibitors also produced cardiorenal protection while controlling blood glucose.SGLT-2 inhibitors have certain positive effects on the heart and kidney through mechanisms such as reducing patients'body weight,improving energy metabolism and lowering blood pressure.This paper briefly describes the importance of SGLT-2 in the clinical diagnosis and treatment process and the protective role of SGLT-2 inhibitors in the heart and kidney.
作者
何苗
蒋立虹
马丽晶
郑锖
He Miao;Jiang Lihong;Ma Lijing;Zheng Qiang(Department of Cardiovascular Medicine,Affiliated Hospital of Kunming University of Science and Technology,Yunnan First People's Hospital,Kunming 650200,China;Department of Cardiovascular Surgery,Affiliated Hospital of Kunming University of Science and Technology,Yunnan First People's Hospital,Kunming 650200,China;Department of Endocrine Metabolism,Affiliated Hospital of Kunming University of Science and Technology,Yunnan First People's Hospital,Kunming 650200,China)
出处
《中国医药》
2023年第1期123-126,共4页
China Medicine
基金
云南省科技厅科技计划(202101AY070001-265)
云南省内分泌与代谢性疾病临床医学中心开放项目(2020LCZXKF-NM003)。
